Our unbiased effector discovery platform allows us to discover the most powerful proximity mechanisms for a given target, enabling the development of highly-efficacious proximity therapeutics for targets previously beyond the reach of medicine.
Browser storage is unavailable. Keep this page open and export your collection before leaving.

General Proximity
Overview
The next generation of induced-proximity medicines.
Product & workflow
Founders & team
Previously Weatherwax Bio
Armand Cognetta
FounderArmand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).
News & product activity
Sources & observations
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsTeam information
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2020 Q1 (quarter only)





